Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 85,271 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 85,271 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $35.52, for a total value of $3,028,825.92. Following the transaction, the chief operating officer directly owned 44,452 shares of the company’s stock, valued at $1,578,935.04. This represents a 65.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total value of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.72, for a total value of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.

Kiniksa Pharmaceuticals International Stock Up 0.8%

Shares of KNSA stock opened at $36.86 on Wednesday. The stock has a 50-day simple moving average of $31.32 and a 200 day simple moving average of $26.77. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $36.93. The stock has a market capitalization of $2.73 billion, a P/E ratio of 921.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Corebridge Financial Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 3.6% in the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock valued at $355,000 after acquiring an additional 549 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. Sound View Wealth Advisors Group LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 4.0% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company’s stock valued at $326,000 after acquiring an additional 568 shares in the last quarter. Finally, Martingale Asset Management L P raised its stake in shares of Kiniksa Pharmaceuticals International by 1.3% in the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock valued at $1,111,000 after acquiring an additional 640 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on KNSA. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, July 9th. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.